Organon & Co. (NYSE:OGN) Shares Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC raised its position in Organon & Co. (NYSE:OGN) by 25.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 44,738 shares of the company’s stock after buying an additional 9,018 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Organon & Co. were worth $645,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd increased its stake in shares of Organon & Co. by 495.5% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares during the period. Headlands Technologies LLC purchased a new stake in Organon & Co. in the 3rd quarter valued at approximately $35,000. EverSource Wealth Advisors LLC increased its position in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock worth $39,000 after purchasing an additional 1,110 shares during the period. Clear Street Markets LLC raised its stake in shares of Organon & Co. by 588.9% during the 3rd quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock worth $40,000 after buying an additional 1,961 shares in the last quarter. Finally, Column Capital Advisors LLC lifted its holdings in shares of Organon & Co. by 148.8% in the 3rd quarter. Column Capital Advisors LLC now owns 2,336 shares of the company’s stock valued at $41,000 after buying an additional 1,397 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group increased their price objective on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 20th.

Organon & Co. Trading Up 1.0 %

OGN stock opened at $18.00 on Tuesday. The firm has a 50 day moving average of $18.05 and a 200-day moving average of $15.63. The company has a market cap of $4.60 billion, a price-to-earnings ratio of 4.50, a PEG ratio of 0.84 and a beta of 0.83. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.79.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. Sell-side analysts forecast that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 annualized dividend and a dividend yield of 6.22%. Organon & Co.’s dividend payout ratio is presently 28.00%.

Insider Activity at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the transaction, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.17% of the stock is owned by corporate insiders.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.